Young E. Whang

7.6k total citations · 2 hit papers
101 papers, 5.6k citations indexed

About

Young E. Whang is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Young E. Whang has authored 101 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Pulmonary and Respiratory Medicine, 42 papers in Molecular Biology and 39 papers in Oncology. Recurrent topics in Young E. Whang's work include Prostate Cancer Treatment and Research (45 papers), PI3K/AKT/mTOR signaling in cancer (18 papers) and Radiopharmaceutical Chemistry and Applications (11 papers). Young E. Whang is often cited by papers focused on Prostate Cancer Treatment and Research (45 papers), PI3K/AKT/mTOR signaling in cancer (18 papers) and Radiopharmaceutical Chemistry and Applications (11 papers). Young E. Whang collaborates with scholars based in United States, Australia and United Kingdom. Young E. Whang's co-authors include Charles L. Sawyers, Xinyi Wu, Elliott Kieff, H. Shelton Earp, Mehran S. Neshat, James L. Mohler, Jerome E. Tanner, Xiu‐Juan Yuan, Douglas T. Fearon and Janis J. Weis and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Young E. Whang

95 papers receiving 5.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway

1998 539 citations Young E. Whang, Charles L. Sawyers et al. profile →
Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression

1998 526 citations Young E. Whang, Charles L. Sawyers et al. profile →

Peers

Countries citing papers authored by Young E. Whang

Since Specialization

Citations

This map shows the geographic impact of Young E. Whang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Young E. Whang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Young E. Whang more than expected).

Fields of papers citing papers by Young E. Whang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Young E. Whang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Young E. Whang. The network helps show where Young E. Whang may publish in the future.

Co-authorship network of co-authors of Young E. Whang

This figure shows the co-authorship network connecting the top 25 collaborators of Young E. Whang. A scholar is included among the top collaborators of Young E. Whang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Young E. Whang. Young E. Whang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A phase 1b, open-label, multicenter study of xaluritamig in patients with biochemical recurrence of prostate cancer after definitive therapy. 2025 ·Journal of Clinical Oncology ·Ben Tran, Kevin D. Courtney, Alexandra Sokolova, Lisa G. Horvath, Daniel C. Danila, Jessica E. Hawley, David Pook, Landon C. Brown, Young E. Whang, (unknown), Kejia Wang, Nicholas A. Zorko	0
2	Tarlatamab for Large Cell Neuroendocrine Carcinoma in a Young Adult: A Case Report 2024 ·JTO Clinical and Research Reports ·Shetal Patel, Young E. Whang, (unknown), Kevin Chen, (unknown), Dante S. Bortone, Benjamin G. Vincent, Jared Weiss	5
3	Waldenström macroglobulinemia with secondary pure red cell aplasia in a patient with metastatic castrate resistant prostate cancer receiving an immune checkpoint inhibitor: a case report 2023 ·Journal of Medical Case Reports ·Vaibhav Kumar, Nathan D. Montgomery, Hendrik W. van Deventer, Young E. Whang	1
4	Feasibility of home-based exercise training in men with metastatic castration-resistant prostate cancer 2022 ·Prostate Cancer and Prostatic Diseases ·Erik D. Hanson, (unknown), (unknown), (unknown), Alexander R. Lucas, Young E. Whang, Matthew I. Milowsky, David B. Bartlett, Michael R. Harrison, Rhonda L. Bitting, Allison M. Deal, Lee Stoner, Anthony C. Hackney, Cláudio L. Battaglini	11
5	A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer 2021 ·PLoS ONE ·(unknown), (unknown), (unknown), (unknown), Mary Dunn, Amir H. Khandani, Paul A. Godley, Tracy L. Rose, Ethan Basch, Matthew I. Milowsky, Young E. Whang, Daniel J. Crona	5
6	Patterns of Recurrence, Detection Rates, and Impact of 18-F Fluciclovine PET/CT on the Management of Men With Recurrent Prostate Cancer 2021 ·Urology ·(unknown), Amir H. Khandani, Ramsankar Basak, Hung‐Jui Tan, Trevor J. Royce, Eric Wallen, Young E. Whang, Tracy L. Rose, Matthew I. Milowsky, Marc A. Bjurlin	4
7	Phase I trial of docetaxel plus lutetium-177-labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 (177Lu‐J591) for metastatic castration‐resistant prostate cancer 2020 ·Urologic Oncology Seminars and Original Investigations ·Jaspreet S. Batra, Muhammad Junaid Niaz, Young E. Whang, Arif Sheikh, Charlene Thomas, Paul J. Christos, Shankar Vallabhajosula, Yuliya Jhanwar, Ana M. Molina, David M. Nanus, Joseph R. Osborne, Neil H. Bander, Scott T. Tagawa	38
8	Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series 2019 ·Journal for ImmunoTherapy of Cancer ·Abdul Rafeh Naqash, (unknown), (unknown), Young E. Whang, (unknown), Paul B. Googe, Frances A. Collichio	17
9	Safety and immunogenicity of a DNA-vaccine immunotherapy in men with biochemically (PSA) relapsed prostate cancer 2017 ·Annals of Oncology ·Neal D. Shore, Elisabeth I. Heath, Luke T. Nordquist, Heather H. Cheng, (unknown), (unknown), Trevor McMullan, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Rahul Atul Parikh, Ronald Tutrone, J. Garcia, Young E. Whang, William K. Kelly, Ildiko Csiki, Mark L. Bagarazzi	1
10	A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer 2012 ·Investigational New Drugs ·Gary R. Hudes, Scott T. Tagawa, Young E. Whang, Ming Qi, Xiang Qin, Thomas A. Puchalski, Manjula Reddy, Mark Cornfeld, Mario A. Eisenberger	54
11	A phase II trial of neoadjuvant erlotinib in patients with muscle‐invasive bladder cancer undergoing radical cystectomy: clinical and pathological results 2010 ·British Journal of Urology ·Raj S. Pruthi, Matthew E. Nielsen, Samuel A. Heathcote, Eric Wallen, W. Kimryn Rathmell, Paul A. Godley, Young E. Whang, Julia R. Fielding, Heather Schultz, Gayle Grigson, Angela B. Smith, William Kim	84
12	Rapamycin inhibits cell proliferation in type I and type II endometrial carcinomas: A search for biomarkers of sensitivity to treatment 2010 ·Gynecologic Oncology ·Victoria Bae‐Jump, Chunxiao Zhou, John F. Boggess, Young E. Whang, Lisa Barroilhet, Paola A. Gehrig	26
13	Involvement of arginine methyltransferase CARM1 in androgen receptor function and prostate cancer cell viability 2006 ·The Prostate ·Samarpan Majumder, Yuanbo Liu, O. Harris Ford, James L. Mohler, Young E. Whang	114
14	Activated Tyrosine Kinase Ack1 Promotes Prostate Tumorigenesis: Role of Ack1 in Polyubiquitination of Tumor Suppressor Wwox 2005 ·Cancer Research ·Nupam P. Mahajan, Young E. Whang, James L. Mohler, H. Shelton Earp	176
15	Heregulin-Induced Activation of HER2 and HER3 Increases Androgen Receptor Transactivation and CWR-R1 Human Recurrent Prostate Cancer Cell Growth 2005 ·Clinical Cancer Research ·Christopher W. Gregory, Young E. Whang, (unknown), (unknown), Yuanbo Liu, Liliana A. Ponguta, Frank S. French, Elizabeth M. Wilson, H. Shelton Earp	107
16	p38 and EGF receptor kinase-mediated activation of the phosphatidylinositol 3-kinase/Akt pathway is required for Zn²⁺-induced cyclooxygenase-2 expression 2005 ·American Journal of Physiology-Lung Cellular and Molecular Physiology ·Weidong Wu, Robert Silbajoris, Young E. Whang, Lee M. Graves, Philip A. Bromberg, James M. Samet	48
17	The PTEN tumor suppressor inhibits telomerase activity in endometrial cancer cells by decreasing hTERT mRNA levels 2005 ·Gynecologic Oncology ·Chunxiao Zhou, Victoria Bae‐Jump, Young E. Whang, Paola A. Gehrig, John F. Boggess	44
18	The PTEN tumor suppressor is a negative modulator of androgen receptor transcriptional activity 2003 ·Journal of Molecular Endocrinology ·Bicheng Nan, Thiti Snabboon, Emmanual Unni, (unknown), Young E. Whang, Marco Marcelli	52
19	PTEN Blocks Tumor Necrosis Factor-induced NF-κB-dependent Transcription by Inhibiting the Transactivation Potential of the p65 Subunit 2002 ·Journal of Biological Chemistry ·Marty W. Mayo, Lee V. Madrid, Sandy D. Westerheide, David R. Jones, Xiu‐Juan Yuan, Albert S. Baldwin, Young E. Whang	107
20	Role for c-Abl tyrosine kinase in growth arrest response to DNA damage 1996 ·Nature ·Zhi-Min Yuan, Yinyin Huang, Young E. Whang, Charles L. Sawyers, Ralph R. Weichselbaum, Surender Kharbanda, Donald Küfe	191

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact